Publication: 3655

Publication: 3655

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of GRIFFIN After 24 Months of Maintenance (AFT-29)

DOI

URL

Google Scholar

Citation:: Blood vol 138 (Supplement 1) 79

Meeting Instance:: ASH 2021
Year:: 2021
Type:: Abstract
Sub type:: Oral
Funding:: AFT
Endpoint:: Secondary-not-in-original
Analysis:: Long-Term-Followup
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 3854

Program:: OGC
Primary Committee:: Myeloma
Sec. Committees:

Pharmas:: Jansen Oncology
Grants:

Corr. Author:
Authors:: Jacob Laubach Johnathan L. Kaufman Douglas W. Sborov Brandi Reeves Cesar Rodriguez Ajai Chari Rebecca Silbermann Luciano J. Costa Larry D. Anderson Jr. Nitya Nathwani Nina Shah Yvonne A. Efebera Sarah A. Holstein Caitlin Costello Andrzej Jakubowiak Tanya M. Wildes Robert Z. Orlowski Kenneth H. Shain Andrew J. Cowan Huiling Pei Annelore Cortoos Sharmila Patel Blake Bartlett Jessica Vermeulen Thomas S. Lin Paul G. Richardson Peter M. Voorhees

Networks:: CA043, CA249, CA824, FL065, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, NC002, NE003, NEWMEXICO, NY021, OH008, OR013

Study: AFT-29 (GRIFFIN)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: